Medexus Pharmaceuticals (MDP.T), a Canadian specialty pharma company focused on the North American markets, has developed a robust drug portfolio that still has lots of room for growth. Due to a hiccup with the FDA requiring more information for an already approved drug, treosulfan, investors became skittish and share price slumped.

Equity Guru founder Chris Parry, jumps in to explain how illogically investors handled the FDA news as Medexus is a strong revenue generator already currently trading at one-third its annual revenue.

Parry lays out the company’s misunderstood value proposition to illustrate the inherent potential for investors to capitalize on a unique growth story at the ground floor.

Enjoy!